ArticleScience (New York, N.Y.)2022
Enhanced T cell effector activity by targeting the Mediator kinase module.
Open access · greenAbstract read
In one paragraph
Article in Science (New York, N.Y.), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 104 papers, 3 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
104citing papers in PubMed, 3 pooled it
12.6field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
104 citing papers in PubMed, 3 syntheses or guidelines pooled it, 126 citations in OpenAlex.
- Mapping the clinical landscape of multifunctional CAR T cells: Targets, trends, and synergies.Molecular therapy : the journal of the American Society of Gene Therapy · 2026Pooled it
- Strategies and mechanisms for the enhancement of chimeric antigen receptor T-cell functions.Science China. Life sciences · 2026Pooled it
- Allogeneic CAR-engineered cellular therapy for relapsed and refractory large B cell lymphoma: a systematic review and meta-analysis.Frontiers in immunology · 2025Pooled it
- Article
- High-Content CRISPR Screening: Methods and Applications.MedComm · 2026Review
- Integrated epigenetic and genetic programming of primary human T cells.Nature biotechnology · 2026Article
- Article
- Surfaceome CRISPR activation screening uncovers ligands regulating tumor sensitivity to NK cell killing.Nature communications · 2026Article
- A Novel Intronic Variant inGenes · 2026Review
- A guide to CAR T cell therapies: development, current status and future prospects.Nature reviews. Immunology · 2026Review
- Cell-autonomous control of CAR signaling and receptor shedding via ADAM17-mediated proteolysis.Cell · 2026Article
- Cell Cycle Sensing Shapes Human T Cell Fate and Exhaustion Programs.bioRxiv : the preprint server for biology · 2026Article
- COVID-19 is associated with epigenetic dysregulation in regulatory B cells linked to recurrent pregnancy loss.Cell communication and signaling : CCS · 2026Article
- Article
- CRISPR/Cas9-Mediated Gene Knockout Reveals a Nonredundant Role for p16European journal of immunology · 2026Article
- Reprogramming Antitumor Immunity: NK Cell Strategies to Navigate the Immunosuppressive Tumor Microenvironment.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- The evolution of display technologies for antibody drug discovery.Trends in biotechnology · 2026Review
- Challenges and advances in CAR-T cell therapy for B-ALL.Biomarker research · 2026Review
- Engineered dCas12f1-SAM enables robust transcriptional activation and gain-of-function screening in primary human cells.Nature communications · 2026Article
- Integrated multi-regional multiomic profiling of breast phyllodes tumours reveals peritumoural immune activation and stromal remodelling.Clinical and translational medicine · 2026Article
44 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
Authors and funding
21 authors at 5 institutions in 1 country.
Katherine A Freitas *Immunology Graduate Program, Stanford University School of Medicine, Stanford, CA, USA.ORCID 0000-0001-9480-7320
Julia A Belk *Department of Computer Science, Stanford University, Stanford, CA, USA.ORCID 0000-0003-4724-6158
Elena SotilloCenter for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA.ORCID 0000-0002-3993-1932
Patrick J QuinnCenter for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA.ORCID 0000-0002-4406-727X
Maria C RamelloCenter for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA.
Meena MalipatlollaCenter for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA.
Bence DanielCenter for Personal Dynamic Regulomes, Stanford University, Stanford, CA, USA.ORCID 0000-0002-2410-8767
Katalin SandorDepartment of Pathology, Stanford University School of Medicine, Stanford, CA, USA.ORCID 0000-0003-2892-4865
Dorota KlyszCenter for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA.ORCID 0000-0002-6733-6110
Jeremy BjelajacCenter for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA.ORCID 0000-0001-7628-1652
Peng XuCenter for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA.
Kylie A BurdsallCenter for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA.ORCID 0000-0001-7089-2532
Victor TieuDepartment of Bioengineering, Stanford University School of Medicine, Stanford, CA, USA.ORCID 0000-0003-0135-9587
Vandon T DuongDepartment of Bioengineering, Stanford University School of Medicine, Stanford, CA, USA.
Micah G DonovanDepartment of Pharmacology, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.ORCID 0000-0002-3463-2570
Evan W WeberCenter for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA.ORCID 0000-0001-5039-2899
Howard Y ChangCenter for Personal Dynamic Regulomes, Stanford University, Stanford, CA, USA.ORCID 0000-0002-9459-4393
Robbie G MajznerCenter for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA.ORCID 0000-0001-6969-8011
Joaquin M EspinosaDepartment of Pharmacology, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.ORCID 0000-0001-9048-1941
Ansuman T Satpathy *Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA.ORCID 0000-0002-5167-537X
Crystal L Mackall *Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA.ORCID 0000-0003-0359-9023
Stanford University · USParker Institute for Cancer Immunotherapy · USUniversity of Colorado Anschutz Medical Campus · USHoward Hughes Medical Institute · USStanford Medicine · US
Funding
Center for Personal Dynamic RegulomesRM1HG007735 · NHGRI · STANFORD UNIVERSITY · PI CHANG, HOWARD Y · 2019 to 2023
$13.8MUnderstanding and Overcoming Resistance to Immunotherapies in Childhood CancersU54CA232568 · NCI · CHILDREN'S HOSP OF PHILADELPHIA · PI MACKALL, CRYSTAL, MARIS, JOHN M · 2018 to 2022
$13.1MMedical Scientist Training ProgramT32GM145402 · NIGMS · STANFORD UNIVERSITY · PI Katrin F. Chua · 2022 to 2026
$10.0McGMP Manufacture, Fill-Finish, Release, Analytical and Stability Testing and Stability Program of a Nanoparticle Based HIV Envelope Vaccine75N93022D00005 · NIAID · INTERNATIONAL AIDS VACCINE INITIATIVE · PI HASSELL, THOMAS · 2022 to 2025
$8.0MLncRNA mechanisms in cancerR35CA209919 · NCI · STANFORD UNIVERSITY · PI CHANG, HOWARD Y · 2016 to 2022
$6.4MTask Area A shall encompass annual follow-up of cohort members, clinical events investigations, study operations, and data analysis and manuscript writing. If implemented, Task A.1 will provide fundin75N92020D00005 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI WATSON, KAROL E · 2020 to 2025
$5.1MUnderstanding Down Syndrome as an InterferonopathyR01AI150305 · NIAID · UNIVERSITY OF COLORADO DENVER · PI ESPINOSA, JOAQUIN M. · 2019 to 2020
$3.5M4DN Interrogation of T Cell Exhaustion in CancerU01CA260852 · NCI · STANFORD UNIVERSITY · PI SATPATHY, ANSUMAN · 2020 to 2024
$2.6MFour Laser, 18 Color Cell Sorter in the SSFFS10RR025518 · NCRR · STANFORD UNIVERSITY · PI HERZENBERG, LEONARD A · 2009 to 2009
$500kNCI NIH HHS R35 CA209919NCI NIH HHS U01 CA260852NCI NIH HHS U54 CA232568NCRR NIH HHS S10 RR025518NHGRI NIH HHS RM1 HG007735NHLBI NIH HHS 75N92020D00005NIAID NIH HHS 75N93022D00005NIAID NIH HHS 75N93023D00005NIAID NIH HHS R01 AI150305NIDA NIH HHS 75N95020D00005NIGMS NIH HHS T32 GM145402ORFDO NIH HHS 75N99020D00005
Abstract
T cells are the major arm of the immune system responsible for controlling and regressing cancers. To identify genes limiting T cell function, we conducted genome-wide CRISPR knockout screens in human chimeric antigen receptor (CAR) T cells. Top hits were
Indexed as
Cyclin CMediator ComplexNeoplasmsReceptors, Chimeric AntigenT-LymphocytesCyclin-Dependent Kinase 8Cyclin-Dependent KinasesGenetic TestingGenome-Wide Association StudyHumansImmunotherapy, AdoptiveTranscription FactorsCCNC protein, humanCyclin CCyclin-Dependent Kinase 8Cyclin-Dependent KinasesMED12 protein, humanMediator ComplexReceptors, Chimeric AntigenTranscription Factors
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.